Literature DB >> 25712944

Prognostic significance of perihematomal edema in acute intracerebral hemorrhage: pooled analysis from the intensive blood pressure reduction in acute cerebral hemorrhage trial studies.

Jie Yang1, Hisatomi Arima1, Guojun Wu1, Emma Heeley1, Candice Delcourt1, Junshan Zhou1, Guofang Chen1, Xia Wang1, Shihong Zhang1, Sungwook Yu1, John Chalmers1, Craig S Anderson2.   

Abstract

BACKGROUND AND
PURPOSE: Controversy exists over the prognostic significance of perihematomal edema (PHE) in intracerebral hemorrhage. We aimed to determine the association of early PHE and clinical outcome among participants of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT) studies.
METHODS: Pooled analyses of computed tomographic substudies in the pilot phase (INTERACT1) and main phase (INTERACT2), both international, prospective, open, blinded end point, randomized controlled trials, of patients with spontaneous intracerebral hemorrhage (<6 hours) and elevated systolic blood pressure, randomly assigned to intensive (target systolic blood pressure, <140 mm Hg) or guideline-based (systolic blood pressure, <180 mm Hg) blood-pressure management. Substudy participants (n=1310; 346 INTERACT1, 964 INTERACT2) had blinded central analyses of digital images from standardized baseline and 24-hour computed tomography. Predictors of death or dependency (modified Rankin scale scores, ≥3) at 90 days were assessed in logistic regression models and reported with odds ratios and 95% confidence intervals. INTERACT studies are registered at ClinicalTrials.gov (NCT00226096 and NCT00716079).
RESULTS: Of 1138 (87%) patients with 2 CTs available for edema analysis and outcome information, time from intracerebral hemorrhage onset to baseline computed tomography, baseline hematoma volume, 24-hour hematoma growth, and intraventricular extension were independent predictors of 24-hour PHE growth. Absolute growth in PHE volume was significantly associated with death or dependency (adjusted odds ratio, 1.17; 95% confidence interval, 1.02-1.33 per 5 mL increase from baseline; P=0.025) at 90 days after adjustment for demographic, clinical, and hematoma parameter prognostic factors. Associations were consistent across various sensitivity analyses.
CONCLUSION: PHE growth is an independent prognostic factor in intracerebral hemorrhage. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096 and NCT00716079.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  cerebral hemorrhage; clinical trial; hypertension

Mesh:

Substances:

Year:  2015        PMID: 25712944     DOI: 10.1161/STROKEAHA.114.007154

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  44 in total

Review 1.  Perihematomal edema: Implications for intracerebral hemorrhage research and therapeutic advances.

Authors:  Magdy Selim; Casey Norton
Journal:  J Neurosci Res       Date:  2018-12-21       Impact factor: 4.164

2.  Influence of Intracerebral Hemorrhage Location on Outcomes in Patients With Severe Intraventricular Hemorrhage.

Authors:  Vahid Eslami; Pouya Tahsili-Fahadan; Lucia Rivera-Lara; Dheeraj Gandhi; Hasan Ali; Adrian Parry-Jones; Lilli S Nelson; Richard E Thompson; Saman Nekoobakht-Tak; Rachel Dlugash; Nichol McBee; Isaam Awad; Daniel F Hanley; Wendy C Ziai
Journal:  Stroke       Date:  2019-06-10       Impact factor: 7.914

3.  Rate of Perihematomal Edema Expansion Predicts Outcome After Intracerebral Hemorrhage.

Authors:  Sebastian Urday; Lauren A Beslow; Feng Dai; Fan Zhang; Thomas W K Battey; Anastasia Vashkevich; Alison M Ayres; Audrey C Leasure; Magdy H Selim; J Marc Simard; Jonathan Rosand; W Taylor Kimberly; Kevin N Sheth
Journal:  Crit Care Med       Date:  2016-04       Impact factor: 7.598

Review 4.  Computed Tomography Imaging Predictors of Intracerebral Hemorrhage Expansion.

Authors:  Xin-Ni Lv; Lan Deng; Wen-Song Yang; Xiao Wei; Qi Li
Journal:  Curr Neurol Neurosci Rep       Date:  2021-03-12       Impact factor: 5.081

5.  Neutrophil-Lymphocyte Ratio and Perihematomal Edema Growth in Intracerebral Hemorrhage.

Authors:  Aaron M Gusdon; Gino Gialdini; Gbambele Kone; Hediyeh Baradaran; Alexander E Merkler; Halinder S Mangat; Babak B Navi; Costantino Iadecola; Ajay Gupta; Hooman Kamel; Santosh B Murthy
Journal:  Stroke       Date:  2017-07-11       Impact factor: 7.914

6.  Perihematomal Edema After Intracerebral Hemorrhage in Patients With Active Malignancy.

Authors:  Aaron M Gusdon; Paul A Nyquist; Victor M Torres-Lopez; Audrey C Leasure; Guido J Falcone; Kevin N Sheth; Lauren H Sansing; Daniel F Hanley; Rachna Malani
Journal:  Stroke       Date:  2019-11-20       Impact factor: 7.914

7.  Treatment of Edema Associated With Intracerebral Hemorrhage.

Authors:  Audrey Leasure; W Taylor Kimberly; Lauren H Sansing; Kristopher T Kahle; Golo Kronenberg; Hagen Kunte; J Marc Simard; Kevin N Sheth
Journal:  Curr Treat Options Neurol       Date:  2016-02       Impact factor: 3.598

8.  Quantitative assessment on blood-brain barrier permeability of acute spontaneous intracerebral hemorrhage in basal ganglia: a CT perfusion study.

Authors:  Haoli Xu; Rui Li; Yuxia Duan; Jincheng Wang; Shuailiang Liu; Yue Zhang; Wenwen He; Xiaotao Qin; Guoquan Cao; Yunjun Yang; Qichuan Zhuge; Jun Yang; Weijian Chen
Journal:  Neuroradiology       Date:  2017-06-03       Impact factor: 2.804

9.  Impact of Perihemorrhagic Edema on Short-Term Outcome After Intracerebral Hemorrhage.

Authors:  Bastian Volbers; Wolfgang Willfarth; Joji B Kuramatsu; Tobias Struffert; Arnd Dörfler; Hagen B Huttner; Stefan Schwab; Dimitre Staykov
Journal:  Neurocrit Care       Date:  2016-06       Impact factor: 3.210

10.  Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage.

Authors:  Santosh B Murthy; Sebastian Urday; Lauren A Beslow; Jesse Dawson; Kennedy Lees; W Taylor Kimberly; Costantino Iadecola; Hooman Kamel; Daniel F Hanley; Kevin N Sheth; Wendy C Ziai
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-07-27       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.